Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy

Immune checkpoint inhibitors (ICIs) such as anti-PD-L1 antibodies are widely used to treat human cancers, and growing evidence suggests that ICIs are promising treatments for canine malignancies. However, only some canine oral malignant melanoma (OMM) cases respond to ICIs. To explore biomarkers pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Maekawa, Naoya, Konnai, Satoru, Asano, Yumie, Sajiki, Yamato, Deguchi, Tatsuya, Okagawa, Tomohiro, Watari, Kei, Takeuchi, Hiroto, Takagi, Satoshi, Hosoya, Kenji, Kim, Sangho, Ohta, Hiroshi, Kato, Yukinari, Suzuki, Yasuhiko, Murata, Shiro, Ohashi, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166720/
https://www.ncbi.nlm.nih.gov/pubmed/35665759
http://dx.doi.org/10.1038/s41598-022-13484-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166720/
https://www.ncbi.nlm.nih.gov/pubmed/35665759
http://dx.doi.org/10.1038/s41598-022-13484-8

Ejemplares similares